Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

ClinicalTrials.gov ID: NCT00108095

Public ClinicalTrials.gov record NCT00108095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV

Study identification

NCT ID
NCT00108095
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
701 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2004
Primary completion
Jul 31, 2005
Completion
Jul 31, 2005
Last update posted
Jan 19, 2017

2004 – 2005

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
GSK Investigational Site Montgomery Alabama 36106
GSK Investigational Site Phoenix Arizona 85032
GSK Investigational Site Arcadia California 91007
GSK Investigational Site Duarte California 91010
GSK Investigational Site Glendale California 91206
GSK Investigational Site Laguna Hills California 92653
GSK Investigational Site Loma Linda California 92354
GSK Investigational Site Pasadena California 91109
GSK Investigational Site San Diego California 92123
GSK Investigational Site Stanford California 94305
GSK Investigational Site Naples Florida 34108
GSK Investigational Site Pensacola Florida 32504
GSK Investigational Site Alpharetta Georgia 30005
GSK Investigational Site Hutchinson Kansas 67502
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Baton Rouge Louisiana 70806
GSK Investigational Site Baltimore Maryland 21229-5299
GSK Investigational Site Jackson Mississippi 39202
GSK Investigational Site New Brunswick New Jersey 8903
GSK Investigational Site New York New York 10016
GSK Investigational Site New York New York 10025
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Pittsburgh Pennsylvania 15213
GSK Investigational Site Charleston South Carolina 29425
GSK Investigational Site Houston Texas 77024
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Houston Texas 77054
GSK Investigational Site San Antonio Texas 78240
GSK Investigational Site Winchester Virginia 22601
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00108095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2017 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00108095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →